BridgeBio enters the pan-KRAS game
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
MAIA throws more money at ateganosine
The THIO-104 study listing is live, along with questions about funding the trial.
Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Imunon looks for an IL-12 Ovation
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
A second shot at PARP1 from Eikon
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Head and neck cancer is next for evorpacept
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Vor looks to answer the Car-T question
Can the company add a Car-T string to its stem cell transplant bow?
The first clinical-stage dual-payload conjugate
Chengdu Kanghong's KH815 enters human testing this month.
